in vivo 28: 919-924 (2014)

Association of SUMO4 M55V and -94Ins/Del Variants with Type-2 Diabetes

SEYMA SOZEN1, CEM HOROZOGLU1, ELIF SINEM BIRELLER1, ZEYNEP KARAALI2 and BEDIA CAKMAKOGLU1

1Department of Molecular Medicine, Institute for Experimental Medicine Research, Istanbul University, Istanbul, Turkey; 2Department of Internal Medicine, Haseki Training and Research Hospital, Istanbul, Turkey

Abstract. Aim: There are two different types of diabetes suggested a common underlying genetic basis (2, 3). To date, mellitus, type 1 and type 2, with still unclear molecular only some shared susceptibility have been reported. mechanisms. In the present study, we aimed to investigate the Ikegami and Ogihara have indicated that type-1 diabetes is role of small ubiquitin-like modifier 4 (SUMO4) M55V and the result of an absolute loss of endogenous insulin due to nuclear factor kappa B1 (NFKB1)-94del/ins in type-2 its autoimmune destruction of insulin-producing cells of the diabetes mellitus. Materials and Methods: We analyzed pancreas, whereas type-2 diabetes occurs due to de-regulated SUMO4 M55V and NFKB1-94del/ins variants in 104 insulin secretion and/or insulin sensitivity and shows patients with type-2 diabetes and 124 healthy controls using variability within each individual (1). The human leukocyte the polymerase chain reaction (PCR) and restriction antigen (HLA) region for insulin-dependent diabetes mellitus fragment length polymorphism (RFLP) techniques. Results: 1 (IDDM1), which is a major susceptibility locus for type-1 The number of SUMO4 M55V MM genotype and M allele diabetes, has also been associated with type-2 diabetes (4, carriers was significantly higher in patients compared to the 5). The IDDM5 locus has been mapped to an approximately control group; however, no efficiency results were found 200-kb interval on 6q25 (6, 7). This new locus related to NFΚB1-94del/ins polymorphism. Conclusion: It contains two genes, small ubiquitin-like modifier 4 (SUMO4) was found that SUMO4 M55V polymorphism and type-2 and MAPK kinase 7 interacting 2 (MAP3K7IP2). diabetes were significantly associated with a possible These may be involved in autoimmunity and inflammation SUMO4 region to type-2 diabetes susceptibility. This through regulation of nuclear factor kappa beta (NF-κB) and preliminary study showed that the distribution of SUMO4 heat shock transcription factor activator 6q25 (6-8). NF-κB is M55V and type-2 diabetes mellitus in Turkish patients may a transcription factor, which plays important roles in form the basis of future research. inflammation, cell survival, angiogenesis and apoptosis. It is located at the signaling pathway terminal of the activated T Diabetes mellitus, a disease described as hyperglycemia cells (9). depending on relative or absolute deficiency of circulating The SUMO4 gene is primarily expressed in the kidney and insulin, comprises of two major forms with distinct immune system (6). Because SUMO4 is located at the sixth pathogeneses, type 1 and type 2. Genetic factors including intron of the mitogen-activated protein (MAP), this location several predisposing genes and environmental effects are indirectly regulates the activation of NFκB in response to involved in both types (1). Although there are distinctive interlukin-10 (IL-10) (10, 11). SUMO4 may regulate the differences in disease pathogenesis, epidemiological data immune response through the substrate inhibitor (IkBα), a show that familial clustering of type 1 and type 2 has suppressor of NFκB, followed by activation of NFκB (7). SUMO4 is an opposite regulator of NFκB. Upstream of NFκB in the signaling pathway, ubiquitination of IkB is the premise of proteasome-mediated degradation of IkBα that Correspondence to: Bedia Cakmakoglu, Department of Molecular frees NFκB to translocate to the nucleus (12). Human SUMO Medicine, Institute for Experimental Medicine Research, Istanbul protein has similar structures to ubiquitine that could University, Vakif Gureba Cad. Capa 34390, Istanbul, Turkey. Tel: conjugate at the same site on IkBα (13). +092 124142000-33305, Fax: +902 125324171, e-mail: [email protected] It has been reported that single nucleotide polymorphisms (SNPs) are related with type-1 diabetes including SUMO4 Key Words: NFKB1, polymorphism, SUMO4, type 2 diabetes. M55V located at the SUMO4/MAP3K7IP2 region in diverse

0258-851X/2014 $2.00+.40 919 in vivo 28: 919-924 (2014) ethnic groups (6, 7). Although there have been reproducible Results association data from Eastern Asian populations (14, 15), results from Caucasian populations showed disparity (6, 7). Demographic data for the study groups are given in Table I. SUMO4 M55V was considered as a causative variant of A statistically significant difference was observed in the IDDM, but with alleles carrying contrary risk (15, 16). A distribution of genotype and allele frequencies in the patient study of 404 patients with type-2 diabetes and 500 controls and control groups for SUMO4 gene polymorphism (p=0,000 in Beijing, China, revealed that carriers of the G allele of χ2=17,56 and p=0,005, χ2=7,84 respectively, Table II). SUMO4 M55V displayed greater risk for type-2 diabetes SUMO4 MV genotype in the control group was statistically (16). Moreover, G allele frequency was markedly increased higher than the patient group and this genotype was four in 403 patients with type-2 diabetes and diabetic nephropathy times more likely to protect against type 2 diabetes (p=0,000, in a study from Taiwan (17). Noso et al. obtained significant χ2=24,47, Odds Ratio (OR)=0,23, %95 Confidence Interval results from 355 Japanese patients on the relationship (CI)=0,12-0,42). SUMO4 MM genotype in the patient group between type-2 diabetes with SUMO4 (18). was also statistically higher than in the control group and this A study through microarray showed that genotype had 4.23 times higher risk for developing type 2 SUMO4 was involved in the pathogenesis of type-2 diabetes diabetes (p=0,000, χ2=21,08, OR=4,23 95% CI=2,37-8,04). and the authors nominated SUMO4 as a new therapeutic Carriers of SUMO4 V+ (VV + MV) genotype in the control target (19). Nevertheless, in Western populations no group (84,6%) was higher than in the patient group (56,5%) association has been found between this variant and type-2 and was three times more likely to protect against type-2 diabetes (13, 20, 14). diabetes (p=0,000, χ2=21,08, OR=0,23; 95% CI=0,12-0,44; Taking into consideration the functional and genetic Data not shown in table). No statistical difference was evidence, we aimed to screen for the SUMO4 M55V and observed in the distribution of genotype and allele NFKB1-94del/ins gene variants in Turkish patients with type frequencies in the patient and control groups for NFΚB1 2 diabetes mellitus. gene polymorphism (p>0.05) (Table III).

Materials and Methods Discussion

Subjects. In total, 228 Turkish subjects, 104 patients with type 2 In the present study we screened 104 patients with type-2 diabetes (68 women and 36 men) and 124 healthy control subjects diabetes and 124 healthy controls for SUMO4 M55V and (76 women and 48 men), were enrolled to our study. The median age of patients with type 2 diabetes and control subjects with no NFΚB1-94ins/del variants to investigate the role of genetic clinical diabetes and no family history of diabetes was 51.5±13.3 variations on the risk of type-2 diabetes. Our results showed and 48.4±10.8 years, respectively. a statistically significant difference in the distribution of genotype and allele frequencies for SUMO4 between patients DNA isolation. After obtaining written informed consent from the and controls. SUMO4 MM genotype was higher in the participants and approval from the Istanbul University’s Ethics patient group than in the controls and had 3.48-times higher Committee, blood specimens were collected in tubes containing risk for developing type-2 diabetes. On the other hand ethylenediaminetetraacetic acid (EDTA). DNA was ex¬tracted from peripheral blood lymphocytes using the salting-out procedure (21). persons who carriers of SUMO4 V allele (VV and MV) had three times protection against to type-2 diabetes. Genotyping. Polymorphisms were genotyped using polymerase chain Genome-wide studies have shown the linkage of type-2 reaction (PCR)/restriction fragment length polymorphism (RFLP) diabetes at chromosome 6q where a susceptibility gene for methods. PCR was used to amplify the region of SUMO4 M55V type 1 diabetes (1DDM5) was mapped, in African–American polymorphism and the NFKB1 94ins/del polymorphism (22, 23). (24), Chinese (25) and Finnish populations (26). Genes on PCR-RFLP with Tru1I restriction (MBI Fermentas, 6q22–26 that influence fasting serum insulin levels have also Lithuania) at 65˚C overnight and Van91I restriction enzyme (MBI been reported (27). In this respect, chromosome 6q may Fermentas, Lithuania) at 65˚C for 2 hours for SUMO4 and NFKB1, respectively, and all the final samples were evaluated using agarose harbor susceptibility genes for type 1 and type 2 diabetes. gel electrophoresis (2%). The obtained bands of 182 bp, 161 and 21 Controversial results were obtained from genotyping studies bp were evaluated as the MM, VV and MV, respectively for of distinct ethnic groups including Asians and Europeans. SUMO4. Accordingly, the bands of 254 bp, 206 and 48 bp were Noso et al. revealed the association between SUMO4 M55V evaluated as WW, DD and WD, respectively for NFKB1. variant and type-1 and type-2 diabetes (19). Studies from Japan have implied a relationship between SUMO4 variant Statistical analysis. The SPSS 11.0 software was used for statistical and type-1 diabetes in the Asian population. Moreover, other analysis (SPPS Inc., Chicago, IL, USA). Chi square test and Fisher test were used to assess the differences of genotype and allele studies have suggested the possibility of a contribution of the frequency between the two groups. Comparison of intergroup SUMO4/MAP3K7IP2 region to both type-1 and type-2 demographic data was determined by using the Student’s t-test. diabetes (19, 28). In this study, it was shown that the GG

920 Sozen et al: SUMO4 and NFΚB1 Polymorphism in Type-2 Diabetes

Table I. Demographic data of the study groups. Table II. Distribution of SUMO4 and allele frequencies in patients and control groups. Parametres Control Patiens p-Value N=104 N=124 SUMO4 genotype Control Patiens and allele (N:104) (N:124) Gender (Woman/Man) 68/36 76/48 0.523 Age (Year) 48.4±10.8 51.5±13.3 0.052 N%N % Glucose (mg/dl) 85.16±5.26 212.9.82±109.65 0.000 HbA1c 4.85±0.32 9.23±3.12 0.000 Genotype Smoking % 42.4 35.7 0.448 MM 16 15.4 54 43.5 Alcohol use % 11.0 7.1 0.782 VV 3 2.9 7 5.6 Obesity % 30.6 MV 85 81.7 63 50.8 LVH (+)% 38.1 Hypertension % 52.0 Allele Myocardial infarction% 25.0 M 117 56.2 171 68.9 V 91 43.7 77 31.4 HbA1c: Glycosylated haemoglobin; LVH: left-ventricular hypertrophy.

allele frequency was higher in patients who were independent Table III. Distribution of NFΚB1 genotype and allele frequencies in patients and control groups. of exogenous insulin than that of insulin-dependent patients, suggesting that insulin secretion was adequate in patients with NFΚB1 genotype Control Patiens higher G allele frequency; however, insulin resistance may and allele (N:104) (N:124) exist. The M55V substitution increased the pathogenesis of chronic inflammation by diminishing SUMO4 inhibition on N % N % κ the activity of NF B; therefore, it was considered as a risk Genotype factor for type-2 diabetes (19). DD 7 6.7 15 12.1 A study from Iran showed that the M55V polymorphism of WW 46 44.2 59 47.6 SUMO4 gene was not associated with type-2 diabetes in DW 51 49.0 50 40.3 Iranian subjects, but the author highlighted that this result may Allele have occurred due to the number of samples (29). No D 65 31.2 80 32.2 association was found with type-1 diabetes in two studies from W 143 68.7 168 67.7 Western populations that investigated the SUMO4 M55V variant: (30) in Lithuania, 100 type-1 diabetes patients and 90 controls (30) and in Sweden, 673 type-1 diabetes and 535 controls (20). Guo et al. in a genotyping and functional study reported that the M55Vsubstitution resulted in 5.5-times greater diabetes was observed but all type-2 diabetes patients were NFκB-transcriptional activity and almost 2-times greater Asians in this study. There are insufficient numbers of expression of IL12B, a NFκB dependent gene in 944 patients studies in Western populations related to type-2 diabetes and with type-1 diabetes from European, American, Italian, French, SUMO4 M55V. In the literature no consensus has been made Spanish, Mexican and Asian populations. A new pathway on M55V substitution and its relationship with type-1 and might be involved in the pathogenesis of type-1 diabetes (7). type-2 diabetes. Asian and Caucasian populations were No association with type-1 diabetes has been indicated in mostly investigated in studies. Genetic heterogeneity has to populations from the United Kingdom, the United States of be considered when assessing the results. America, Ireland, Finland, Romania and Norway (15). Based Activation of NFκB could be depressed by SUMO, which on these results, Lin et al. (31) found a significant association regulates modification of IκBα (12, 13). In several studies, of SUMO4 M55V polymorphism with type-1 diabetes in their the suppression of autoimmune responses by down-regulation meta-analysis of 9,190 cases and 10,456 healthy controls of the transcription factor NFκB has been found to be related (including sixteen case-control studies) in an Asian population with the SUMO4 function. Abnormal NFκB signaling and a significant association of SUMO4 M55V polymorphism pathway activation has also been related with type 1 diabetes. with type-1 diabetes in a Caucasian population . IκBα is a crucial factor for SUMO4 in the regulation of the Six different studies based on the Asian population were NFκB pathway because it is one of the most important included in this meta-analysis concerning the correlation of inhibitors for NFκB (37). NFκB, a transcriptional factor for M55V and type 2 diabetes (19, 26, 32-36). A significant inflammation, is relevant with the pathogenesis of diabetes association of SUMO4 M55V polymorphism with type-2 mellitus. Moreover, the interaction between NFκB and IkBα

921 in vivo 28: 919-924 (2014) is crucial for insulin resistance (38). Insulin resistance could 7 Guo D, Li M, Zhang Y, Yang P, Eckenrode S, Hopkins D, Zheng be stimulated by the activation of the inflammation signaling W, Purohit S, Podolsky RH, Muir A, Wang J, Dong Z, Brusko pathway. It was concluded that this was a functional T, Atkinson M, Pozzilli P, Zeidler A,Raffel LJ, Jacob CO, Park Y, Serrano-Rios M, Larrad MT, Zhang Z, Garchon HJ, BachJF, polymorphism, which modifies the association between Rotter JI, She JX, Wang CY: A functional variant of SUMO4, a polyunsaturated fatty acids (PUFA) intake and plasma high- new I kappa B alpha modifier, is associated with type 1 diabetes. density lipoprotein (HDL)-cholesterol in two distinct Nat Genet 36: 837-841, 2004. populations. Furthermore, we genotyped NFKB1-94ins/del 8 Huang S, DeGuzman A, Bucana CD and Fidler IJ: Nuclear polymorphism in Turkish patients as a possible candidate that factor-kappaB activity correlates with growth, angiogenesis, and may be linked to type 2 diabetes. metastasis of human melanoma cells in nude mice. Clin Cancer Res 6: 2573-2581, 2000. Conclusion 9 Takaesu G, Kishida S, Hiyama A, Yamaguchi K, Shibuya H, Irie K, Ninomiya-Tsuji J and Matsumoto K: TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking Based on our Turkish patients’ data, we showed that type-2 TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol diabetes was significantly associated supporting the Cell 5: 649-658, 2005. possibility of a contribution of the SUMO4 region to type 2 10 Kanayama A, Seth RB, Sun L, Chee-Kwee Ea CH, Hong M, diabetes susceptibility with SUMO4 M55V polymorphism. Shaito A, Chiu Y, Deng L,Chen ZJ: TAB2 and TAB3 activate the It was concluded that SUMO4 affects type-2 independently NF-kappaB pathway through binding to polyubiquitin chains. from NFΚB1, because no association with type 2 diabetes Mol Cell 4: 535-548, 2004. 11 Bayer P, Arndt A, Metzger S, Melchior F, Jaenicke R and Becker and the NFKB1 -94ins/del variant was shown in our study. J: Structure determination of the small ubiquitin-related modifier SUMO-1. J Mol Biol 280: 275-286, 1998. Conflicts of Interest 12 Desterro JM, Rodriguez MS and Hay RT: SUMO-1 modification of IkB‘‘alfa’’ inhibits NF-kB activation. Mol Cell 2: 233-239, None declared. 1998. 13 Qu H, Bharaj B, Liu XQ, Curtis JA, Newhook LA, Paterson AD, Acknowledgements Hudson TJ and Polychronakos C: Assessing the validity of the association between the SUMO4 M55V variant and risk of type This work was supported by the Research Fund of Istanbul 1 diabetes. Nat Genet 37: 111-112, 2005. University. (Project No: 6743). We would like to thank to Mr. David 14 Smyth DJ, Howson JM, Lowe CE, Lam AC, Nutland S, Chapman for English editing. Hutchings J, Tuomilehto-Wolf E, Tuomilehto J, Guja C, Ionescu- Tîrgoviste C, Undlien DE,Rønningen KS, Savage D, Dunger References DB, Twells RC, McArdle WL, Strachan DP, Todd JA: Assessing the validity of the association between the SUMO4 M55V 1 Ikegami H and Ogihara T: Genetics of insulin-dependent variant and risk of type 1 diabetes. Nat Genet 37: 110-111, 2005. diabetes mellitus. Endocr J 43(6): 605-613, 1996. 15 Davies JL, Cucca F and Goy JV: Saturation multipoint linkage 2 Dahlquist G, Blom L, Tuvemo T, Nystrom L and Sandstrom A: mapping of chromosome 6q in type 1 diabetes. Hum Mol Genet The Swedish childhood diabetes study: results from a nine year 5: 1071-1074, 1996. case register and a one year case-referent study indicating that 16 Pu LM, Nan N, Yang Z and Jin ZN: Association between type 1 (insulin-dependent) diabetes mellitus is associated with SUMO4 polymorphisms and type 2 diabetes mellitus. Yi Chuan both type 2 (non-insulin-dependent) diabetes mellitus and 34(3): 315-325, 2012. autoimmune disorders. Diabetologia 32: 2-6, 1989. 17 Lin HY, Wang CL, Hsiao PJ, Lu YC, Chen SY, Lin KD, Hsin 3 Li H, Lindholm E, Almgren P, Gustafsson A, Forsblom C, Groop SC, Hsieh MC,Shin SJ: SUMO4 M55V variant is associated L and Tuomi T: Possible human leukocyte antigen-mediated with diabetic nephropathy in type 2 diabetes. Diabetes 56: 1177- genetic interaction between type 1 and type 2 diabetes. J Clin 1180, 2007. Endocrinol Metab 86: 574-582, 2001. 18 Noso S, Fujisawa T, Kawabata Y, Asano K, Hiromine Y, Fukai 4 Rich SS, French LR, Sprafka JM, Clements JP and Goetz FC: A, Ogihara T and Ikegami H: Association of small ubiquitin-like HLA-associated susceptibility to type 2 (non-insulin-dependent) modifier 4 (SUMO4) variant, located in IDDM5 locus, with type diabetes mellitus: the Wadena City Health Study. Diabetologia 2 diabetes in the Japanese population. J Clin Endocrinol Metab 36: 234-238, 1993. 92(6): 2358-2362, 2007. 5 Tuomilehto-Wolf E, Tuomilehto J, Hitman GA, Nissinen A, Stengard 19 Sengupta U, Ukil S, Dimitrova N and Agrawal S: Expression- J, Pekkanen J, Kivinen P, Kaarsalo E, Karvonen MJ: Genetic Based Network Biology Identifies Alterationin Key Regulatory susceptibility to non-insulin dependent diabetes mellitus and glucose Pathways of Type 2 Diabetes and Associated Risk/Complications. intolerance are located in HLA region. BMJ 307: 155-159, 1993. PLos One 7 4 12 e8100, 2009. 6 Bohren KM, Nadkarni V, Song JH Gabbay KH and Owerbach 20 Sedimbi SK, Luo XR, Sanjeevi CB; Swedish Childhood DA: M55V polymorphism in a novel SUMO gene (SUMO-4) Diabetes Study Group; Diabetes Incidence in Sweden Study differentially activates heat shock transcription factors and is Group, Lernmark A, Landin-Olsson M, Arnqvist H, Björck E, associated with susceptibility to type I diabetes mellitus. J Biol Nyström L, Ohlson LO, Scherstén B, Ostman J, Aili M, Bååth Chem 279: 27233-27238, 2004. LE, Carlsson E, Edenwall H, Forsander G, Granström BW,

922 Sozen et al: SUMO4 and NFΚB1 Polymorphism in Type-2 Diabetes

Gustavsson I, Hanås R, Hellenberg L, Hellgren H, Holmberg E, 31 Lin HY, Li SL, Yu ML, Hsiao PJ, Hsieh MC, Lin KD, Wang CL, Hörnell H, Ivarsson SA, Johansson C, Jonsell G, Kockum K, Wang TN and Shin SJ: Small ubiquitin-like modifier-4 Met55Val Lindblad B, Lindh A, Ludvigsson J, Myrdal U, Neiderud J, polymorphism is associated with glycemic control of Type 2 Segnestam K, Sjöblad S, Skogsberg L, Strömberg L, Ståhle U, diabetes mellitus in Taiwan. J Endocrinol Invest 33: 401-405, Thalme B, Tullus K, Tuvemo T, Wallensteen M, Westphal O, 2010. Dahlquist G and Aman J: SUMO4 M55V polymorphism affects 32 Silander K, Scott LJ, Valle TT, Mohlke KL, Stringham HM, susceptibility to type I diabetes in HLA DR3- and DR4-positive Wiles KR, Duren WL,Doheny KF, Pugh EW, Chines P, Narisu Swedish patients. Genes Immun 8(6): 518-521, 2007. N, White PP, Fingerlin TE, Jackson AU, Li C,Ghosh S, 21 Miller SA, Dykes DD, Polesky HS: Simple salting-out procedure Magnuson VL, Colby K, Erdos MR, Hill JE, Hollstein P, for extracting DNA from human nucleated cells. Nucleic Acid Humphreys KM, Kasad RA, Lambert J, Lazaridis KN, Lin G, Res 16: 1215, 1988. Morales-Mena A, Patzkowski K, Pfahl C,Porter R, Rha D, Segal 22 Park Y, Park S, Kang J, Yang S, Kim D: Assessing the validity of L, Suh YD, Tovar J, Unni A, Welch C, Douglas JA,Epstein MP, the association between the SUMO4 M55V variant and risk of Hauser ER, Hagopian W, Buchanan TA, Watanabe RM, type 1 diabetes. Nat Genet 37(2): 112, 2005. Bergman RN, Tuomilehto J,Collins FS, Boehnke M.: A large set 23 Lewander A, Butchi AK, Gao J, He LJ, Lindblom A, Arbman G, of Finnish affected sibling pair families with type 2 diabetes Carstensen J, Zhang ZY and Sun XF: Swedish Low-Risk suggests susceptibility loci on 6, 11, and 14. Colorectal Cancer Study Group. Polymorphism in the promoter Diabetes 53: 821-829, 2004. region of the NFKB1 gene increases the risk of sporadic 33 Shimada T, Furukawa Y, Furuta H, Yasuda K, Matsuno S, colorectal cancer in Swedish but not in Chinese populations. Kusuyama A, Doi A, Nishi MSasaki H, Sanke T, Nanjo K: Scand J Gastroenterol 42(11): 1332-1338, 2007. SUMO4 Met55Val polymorphism is associated with coronary 24 Sale MM, Freedman BI, Langefeld CD, Williams AH, Hicks PJ, heart disease in Japanese type 2 diabetes individuals. Diabetes Colicigno CJ, Beck SR, Brown WM, Rich SS, Bowden DW: A Res Clin Pract 85: 85-89, 2009. genome-wide scan for type 2 diabetes in African–American 34 Li B, Li HF,YM. W: Correlation between 163 A/G families reveals evidence for a locus on chromosome 6q. polymorphism of SUMO4 gene and diabetic retinopathy. Journal Diabetes 53: 830-837, 2004. of Kunming Medical University 4: 6, 2010. 25 Xiang K, Wang Y and Zheng T: Genome-wide search for type 2 35 Ji ZZ, Dai J,Xu YC: Association between small ubiquitin-like diabetes/impaired glucose homeostasis susceptibility genes in the modifier 4 M55V polymorphism with type 2 diabetes and related Chinese: significant linkage to chromosome 6q21–q23 and factors. Chin J Diabetes Mellitus 2: 344-348, 2010. chromosome 1q21–q24. Diabetes 53: 228-234, 2004. 36 Mora A, Youn J, Keegan A and Boothby M: NF-kappa B/Rel 26 Duggirala R, Blangero J, Almasy L, Arya R, Dyer TD, Williams participation in the lymphokine-dependent proliferation of T KL, Leach RJ, O’Connell P and Stern MP: A major locus for lymphoid cells. J Immunol 166: 2218-2227, 2010. fasting insulin concentrations and insulin resistance on 37 Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M chromosome 6q with strong pleiotropic effects on obesity-related and Shoelson SE: Reversal of obesity- and diet-induced insulin phenotypes in nondiabetic Mexican Americans. J Hum Gene 68: resistance with salicylates or targeted disruption of Ikkbeta. 1149-1164, 2001. Science 293: 1673-1677, 2001. 27 Park Y, Park S, Kang J, Yang S and Kim D: Assessing the 38 Fontaine-Bisson B, Wolever TM, Connelly PW, Corey PN and validity of the association between the SUMO4 M55V variant El-Sohemy A: NF-kappaB -94Ins/Del ATTG polymorphism and risk of type 1 diabetes. Nat Genet 37: 112-113, 2005. modifies the association between dietary polyunsaturated fatty 28 Fallah S, Jafarzadeh M, Hedayati M: No association of the acids and HDL-cholesterol in two distinct populations. SUMO4 polymorphism M55V variant in type 2 diabetes in Atherosclerosis 204(2): 465-467, 2009. Iranian subjects. Diabetes Res Clin Pract 90: 191-195, 2010. 29 Tang S, Peng W, Wang C, Tang H and Zhang Q: Association of the PTPN22 gene (+1858C/T, -1123G/C) polymorphisms with type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetes Res Clin Pract 97(3): 446-452, 2012. 30 Sedimbi SK, Shastry A, Park Y, Rumba I and Sanjeevi CB: Association of SUMO4 M55V polymorphism with autoimmune Received May 28, 2014 diabetes in Latvian patients. Ann NY Acad Sci 1079: 273-277, Revised July 9, 2014 2006. Accepted July 11, 2014

923